NIKKEI 225
26,739.03 +336.19 (+1.27%) HANG SENG
20,717.24 +596.56 (+2.96%) CRUDE OIL
110.35 +0.46 (+0.42%) GOLD FUTURES
1,845.10 +3.90 (+0.21%) DOW
31,261.90 +8.77 (+0.03%) BTC-GBP
23,660.84 +299.41 (+1.28%)
Valbiotis SA (ALVAL.PA)
| Previous close | 5.36 |
| Open | 5.36 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 5.30 - 5.46 |
| 52-week range | 4.01 - 7.48 |
| Volume | |
| Avg. volume | 11,531 |
| Market cap | 51.549M |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.54 |
| Earnings date | 30 Sept 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 14.00 |
- Business Wire
Valbiotis Announces the Release of the Universal Registration Document
LA ROCHELLE, France, May 19, 2022--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / PME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases, announces that its Universal Registration Document was filed to the French Financial Markets Regulator (AMF) May 19, 2022.
- Business Wire
Valbiotis - Combined Shareholders General Meeting Held on May 5, 2022
LA ROCHELLE, France, May 06, 2022--Regulatory News: Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA / PME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases, announces its Combined Shareholders Meeting was held on May 5, 2022 at Espace Encan, La Rochelle, under the chairmanship of Sébastien PELTIER, Chairman of the Board of Directors, and that all the resolutions submitted for voting have been adopted by its shareho
- Business Wire
Valbiotis Announces the First Visit of the First Patient in the TOTUM•63 Mode of Action Clinical Study Conducted by the INAF1, in Partnership With Nestlé Health Science
LA ROCHELLE, France, April 28, 2022--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the first visit of the first patient in the TOTUM•63 mode of action clinical study conducted by the Laval University Institute of Nutrition and Functional Foods (INAF) in Quebec City, in partnership with Nestlé Health Science. The study has now b
